Drug
Flumatinib Mesylate QD
Flumatinib Mesylate QD: highest development phase Phase 2, developed by Hansoh Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Flumatinib mesylate tablet 600 mg qd NCT02511340 | Phase 2 | Chronic Myelogenous Leukemia |
Latest
No recent events.
Follow Flumatinib Mesylate QD on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.